PROKIDNEY CORP. (PROK) Form 10-Q — May 15, 2026
ProKidney Corp. reported a net loss of $20.0 million for the three months ended March 31, 2026, driven by $33.8 million in research and development expenses primarily related to its Phase 3 PROACT 1 trial for rilparencel. The company holds $224.9 million in cash and marketable securities, providing a liquidity runway into mid-2027. It generated $226,000 in revenue from leasing activities, with no product sales revenue.
Key figures
- Revenue
- 226000
- Total Debt
- 3783000
- Total Assets
- 292784000
- Ga Expense
- 11317000
- Rd Expense
- 33842000
- Interest Income
- 2327000
- Atm Capacity Remaining
- 175000000
- Marketable Securities
- 123049000
Price after filing
1 day: 0.0%7 days: +2.3%30 days: -2.9%
Close on the filing date to close N calendar days later (from $1.71). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.